Advantage Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Advantage Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$11K	Sell	300 -1,000	-77%	-$30.3K	0.01%	628
2019 Q2	$35K	Hold	1,300	–	–	0.03%	414
2019 Q1	$35K	Hold	1,300	–	–	0.03%	415
2018 Q4	$21K	Hold	1,300	–	–	0.02%	497
2018 Q3	$27K	Buy	1,300 +900	+225%	+$14.2K	0.02%	517
2018 Q2	$6K	Sell	400 -1,550	-79%	-$27.6K	﹤0.01%	724
2018 Q1	$44K	Buy	1,950 +256	+15%	+$7.09K	0.02%	402
2017 Q4	$51K	Buy	1,694 +283	+20%	+$9.05K	0.02%	390
2017 Q3	$53K	Sell	1,411 -100	-7%	-$3.25K	0.02%	380
2017 Q2	$42K	Buy	1,511 +506	+50%	+$15.1K	0.01%	416
2017 Q1	$35K	Buy	1,005 +150	+18%	+$5.29K	0.01%	430
2016 Q4	$25K	Buy	855 +400	+88%	+$10.6K	0.01%	466
2016 Q3	$14K	Buy	455 +154	+51%	+$5.22K	0.01%	556
2016 Q2	$10K	Buy	301 +1	+0.3%	+$33	﹤0.01%	582
2016 Q1	$8K	Buy	+300	New	+$6.54K	﹤0.01%	587

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Advantage Investment Management's ACAD Position: Q3 2019 in Review

Advantage Investment Management reduced its Acadia Pharmaceuticals (ACAD) stake by 77% in Q3 2019, selling an estimated $30.3K and leaving 300 shares worth $11K. The position accounts for 0.01% of the portfolio, ranked #628.

Advantage Investment Management first reported a position in ACAD in Q1 2016 and has held it in 15 quarters since. The position peaked at $53K in Q3 2017. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

Advantage Investment Management held 300 shares of Acadia Pharmaceuticals worth $11K as of Q3 2019.
Advantage Investment Management sold 1,000 Acadia Pharmaceuticals shares in Q3 2019, an estimated $30.3K.
Acadia Pharmaceuticals made up 0.01% of Advantage Investment Management's portfolio in Q3 2019, its #628 holding.
Advantage Investment Management first reported a position in Acadia Pharmaceuticals in Q1 2016 and has held it in 15 quarters since.
Advantage Investment Management's Acadia Pharmaceuticals position peaked at $53K in Q3 2017.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.